Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) hit a new 52-week high on Monday . The stock traded as high as $131.94 and last traded at $131.89, with a volume of 625284 shares trading hands. The stock had previously closed at $131.81.
Wall Street Analyst Weigh In
ITCI has been the topic of a number of recent analyst reports. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Mizuho lowered Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and lowered their price objective for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Piper Sandler restated a "neutral" rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Finally, StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research note on Friday, March 28th. They issued a "hold" rating for the company. Eleven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $106.23.
View Our Latest Stock Report on ITCI
Intra-Cellular Therapies Stock Performance
The firm has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. The business's 50-day moving average is $129.53 and its two-hundred day moving average is $101.03.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.
Institutional Investors Weigh In On Intra-Cellular Therapies
A number of hedge funds have recently added to or reduced their stakes in ITCI. MassMutual Private Wealth & Trust FSB grew its position in shares of Intra-Cellular Therapies by 124.3% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 133 shares during the last quarter. M&T Bank Corp boosted its stake in Intra-Cellular Therapies by 2.2% during the 4th quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company's stock valued at $526,000 after purchasing an additional 138 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in Intra-Cellular Therapies by 1.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company's stock worth $748,000 after purchasing an additional 141 shares during the last quarter. CIBC Asset Management Inc increased its stake in shares of Intra-Cellular Therapies by 5.3% in the fourth quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company's stock valued at $247,000 after purchasing an additional 150 shares during the period. Finally, Pallas Capital Advisors LLC raised its holdings in shares of Intra-Cellular Therapies by 6.4% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company's stock valued at $266,000 after buying an additional 192 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors.
About Intra-Cellular Therapies
(
Get Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Featured Stories
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
